This article does not predict the outcome of FDA's pending action on the 503B Bulks List or how altRx specifically will be affected
While generally safe and well-tolerated, individuals with copper metabolism disorders, such as Wilsons disease, should avoid this treatment
Aqua (water), Propanediol, Butylene Glycol, Glycerin, Caffeine, Biotinoyl Tripeptide-1, Acetyl Tetrapeptide-3, Larix Europaea Wood Extract, Pisum Sativum Extract, Scutellaria Baicalensis Root Extract, Triticum Vulgare Germ Extract, Glycine Soja Germ Extract, Trifolium Pratense Flower Extract, Camellia Sinensis Leaf Extract, Apigenin, Oleanolic Acid, Arginine, Glycine, Calcium Gluconate, Zinc Chloride, Lactic Acid, Gluconolactone, Dextran, Maltodextrin, Hydroxyethylcellulose, Xanthan Gum, Pentylene Glycol, Dimethyl Isosorbide, Polysorbate 20, PPG-26-buteth-26, PEG-40 Hydrogenated Castor Oil, Trisodium Ethylenediamine Disuccinate, Sodium Metabisulfite, Sodium Benzoate, Phenoxyethanol, Chlorphenesin
Many patients and providers view GLP-1 therapy similarly to antihypertensive or statin use: stopping creates the same disease risk that existed before
Int J Clin Pract 75(2):e13731